These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38558330)

  • 1. High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index.
    García-Escobar A; Lázaro-García R; Cabrera JÁ; Jurado-Román A; Moreno R
    Int J Cardiovasc Imaging; 2024 Apr; 40(4):945-948. PubMed ID: 38558330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness.
    García-Escobar A; Vera-Vera S; Tébar-Márquez D; Rivero-Santana B; Jurado-Román A; Jiménez-Valero S; Galeote G; Cabrera JÁ; Moreno R
    Microvasc Res; 2023 Nov; 150():104598. PubMed ID: 37633337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
    Gotto AM
    Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.
    Raggi P; Genest J; Giles JT; Rayner KJ; Dwivedi G; Beanlands RS; Gupta M
    Atherosclerosis; 2018 Sep; 276():98-108. PubMed ID: 30055326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis.
    Hafiane A; Daskalopoulou SS
    Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation in atherosclerosis: transition from theory to practice.
    Libby P; Okamoto Y; Rocha VZ; Folco E
    Circ J; 2010 Feb; 74(2):213-20. PubMed ID: 20065609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation.
    Zhang RS; Weber BN; Araiza-Garaygordobil D; Garshick MS
    Curr Cardiol Rep; 2024 May; 26(5):423-434. PubMed ID: 38573553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis.
    van Diepen JA; Berbée JF; Havekes LM; Rensen PC
    Atherosclerosis; 2013 Jun; 228(2):306-15. PubMed ID: 23518178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.
    Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F
    Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
    Ridker PM
    Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting inflammation in cardiovascular diseases. still a neglected field?
    Gómez-Guerrero C; Mallavia B; Egido J
    Cardiovasc Ther; 2012 Aug; 30(4):e189-97. PubMed ID: 21884009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
    Vrablik M; Corsini A; Tůmová E
    Curr Atheroscler Rep; 2022 Mar; 24(3):161-169. PubMed ID: 35174437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
    Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
    Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.